RecruitingNot ApplicableNCT04150198

MECHANISMS OF NEURONAL RESILIENCE IN ALZHEIMER'S DISEASE AND ITS FOCAL VARIANTS: A PET/MR STUDY


Sponsor

Institut National de la Santé Et de la Recherche Médicale, France

Enrollment

45 participants

Start Date

Dec 8, 2021

Study Type

INTERVENTIONAL

Conditions

Summary

Patients with Alzheimer's disease and with early onset of symptoms (\<65 years) (AD-Y) have a multi-domain cognitive deficit, whereas memory disorders (typical of the elderly patient's AD) are less often in the foreground. In addition, some MA-J have an atypical phenotype indicating focal brain damage, although they have the same pathological lesions: amyloid deposits and tau protein deposition (DNF). This is the case of posterior cortical atrophy (PCA) characterized by complex visual disturbances and atrophy affecting the more posterior regions of the brain. Based on the clinical profile of PCA patients, a more refined anatomo-clinical classification was proposed, distinguishing a rather "ventral" form and a rather "dorsal" form. The recent arrival of tau-specific PET tracers now makes it possible to evaluate in vivo fibrillary neurodegeneration (FND), which is well correlated with the severity of cognitive disorders. Advances in MRI have shown that each neurodegenerative syndrome targets a large-scale neural network, which in turn shows a vulnerability for a specific biological disease. In the case of AD, the reason for such a difference in cognitive and anatomical impairment between patients with diffuse involvement and others with more focal involvement is not known. One possible explanation is the existence, in focal forms, of neuronal mechanisms that oppose vulnerability. These mechanisms may correspond to the so-called "resilience" phenomenon, defined as resistance to a neuropathological process by the ability to optimize cognitive performance via the efficient recruitment of neural networks. The mechanisms underlying resilience in neurodegeneration are unknown. Their identification is very important for the management and treatment of AD.


Eligibility

Min Age: 40 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study uses advanced brain scanning (PET and MRI) to better understand why some people with Alzheimer's disease decline faster than others. Researchers are looking at brain resilience — essentially, what protects some neurons from damage — in classic Alzheimer's and in rarer variants that affect language or vision rather than memory. **You may be eligible if...** - You are between 40 and 80 years old - You are affiliated with a social security insurance plan (in France) - You have a confirmed or suspected Alzheimer's diagnosis (based on spinal fluid tests or amyloid PET scan), OR you are a healthy volunteer for comparison - You are willing to sign an informed consent form **You may NOT be eligible if...** - You do not meet the specific clinical or biomarker criteria for Alzheimer's or the variant being studied - You are unable to participate in the brain imaging procedures Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICETEP/IRM

All participants will have a PET / MRI examination including: i) a 30-minute PET scan, 80 minutes after intravenous injection of 240 MBq of 18F-AV1451 ± 10% ii) a ZTE sequence (for attenuation correction of PET images), a 3D T1 anatomical sequence, a diffusion MRI, a functional MRI at rest (total duration: 45 minutes). These acquisitions will be made during the same exam session on a hybrid PET / MRI camera allowing simultaneous acquisitions. This visit lasts about 3 hours.


Locations(2)

Service Hospitalier Frédéric Joliot SHFJ

Orsay, France

Service de Médecine Nucléaire - Hopital La Pitié Salpetriere

Paris, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04150198


Related Trials